Anika Therapeutics Inc (ANIK)

51.81
NASDAQ : Health Care
Prev Close 51.81
Day Low/High 0.00 / 0.00
52 Wk Low/High 30.93 / 54.96
Avg Volume 149.60K
Exchange NASDAQ
Shares Outstanding 14.33M
Market Cap 750.64M
EPS 2.10
P/E Ratio 23.49
Div & Yield N.A. (N.A)

Latest News

Here's Whats Next for Anika Therapeutics Post-Breakout

Here's Whats Next for Anika Therapeutics Post-Breakout

The charts are showing a long-term price target of $76.

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a new lifetime high candidate

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...

3 Small Biotechs That Look Very Healthy

Peter Lynch and other market legends would love these names.

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...

Anika Reports First Quarter 2016 Financial Results

Anika Reports First Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics To Issue First-Quarter 2016 Financial Results And Business Highlights On Wednesday, April 27

Anika Therapeutics To Issue First-Quarter 2016 Financial Results And Business Highlights On Wednesday, April 27

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2016 financial results after the close of the market on Wednesday, April 27, 2016 and to hold a conference call...

Anika Appoints New Chief Medical Officer And Chief Operations Officer

Anika Appoints New Chief Medical Officer And Chief Operations Officer

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the executive...

Anika Therapeutics Wins CE Mark Approval For Cingal® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Wins CE Mark Approval For Cingal® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid "HA" technology, today announced that it received CE Mark...

Commit To Purchase Anika Therapeutics At $40, Earn 13.1% Annualized Using Options

Commit To Purchase Anika Therapeutics At $40, Earn 13.1% Annualized Using Options

Investors eyeing a purchase of Anika Therapeutics Inc. stock, but cautious about paying the going market price of $44.09/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Anika Therapeutics Announces $25 Million Accelerated Share Repurchase

Anika Therapeutics Announces $25 Million Accelerated Share Repurchase

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will enter into an...

Anika Therapeutics Delivers Strong Performance With Record Product Revenue For The Fourth Quarter And Full Year 2015

Anika Therapeutics Delivers Strong Performance With Record Product Revenue For The Fourth Quarter And Full Year 2015

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics To Present At The 2016 Canaccord Genuity Musculoskeletal Conference On March 1

Anika Therapeutics To Present At The 2016 Canaccord Genuity Musculoskeletal Conference On March 1

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Therapeutics To Issue Fourth-Quarter 2015 Financial Results And Business Highlights On Wednesday, February 24

Anika Therapeutics To Issue Fourth-Quarter 2015 Financial Results And Business Highlights On Wednesday, February 24

Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its fourth-quarter 2015 financial results after the close of the market on Wednesday, February 24, 2016 and to hold a conference...

Anika Therapeutics, Inc. Announces First Patient Enrolled In FastTRACK Phase III HYALOFAST® Study

Anika Therapeutics, Inc. Announces First Patient Enrolled In FastTRACK Phase III HYALOFAST® Study

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced the enrollment of the first...

Commit To Purchase Anika Therapeutics At $35, Earn 13.7% Annualized Using Options

Commit To Purchase Anika Therapeutics At $35, Earn 13.7% Annualized Using Options

Investors eyeing a purchase of Anika Therapeutics Inc. shares, but tentative about paying the going market price of $38.55/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a weak on high relative volume candidate

Anika Therapeutics Announces Decision To Proceed With CINGAL® Premarket Review Through FDA's Center For Drug Evaluation And Research

Anika Therapeutics Announces Decision To Proceed With CINGAL® Premarket Review Through FDA's Center For Drug Evaluation And Research

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that the U.

Anika Therapeutics To Present At The 27th Annual Piper Jaffray Healthcare Conference On December 1

Anika Therapeutics To Present At The 27th Annual Piper Jaffray Healthcare Conference On December 1

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Therapeutics Announces Health Canada Approval Of CINGAL® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Announces Health Canada Approval Of CINGAL® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced Health Canada approval of...

Anika Appoints Richard Hague To Role Of Chief Commercial Officer

Anika Appoints Richard Hague To Role Of Chief Commercial Officer

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, announced the appointment of Richard...

Anika Therapeutics Reports Robust Financial Performance And Continued Progress On Key Fronts In Third Quarter Of 2015

Anika Therapeutics Reports Robust Financial Performance And Continued Progress On Key Fronts In Third Quarter Of 2015

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics (ANIK): The Next Biotech Breakout You Don't Want to Miss

Anika Therapeutics (ANIK): The Next Biotech Breakout You Don't Want to Miss

Amid the breakout of many names today, we've found an interesting biotech stock that could follow the trend up.

Anika Therapeutics To Issue Third-Quarter 2015 Financial Results And Business Highlights On Wednesday, October 28

Anika Therapeutics To Issue Third-Quarter 2015 Financial Results And Business Highlights On Wednesday, October 28

Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its third-quarter 2015 financial results after the close of the market on Wednesday, October 28, 2015, and hold a conference call...

Anika Therapeutics Becomes Oversold (ANIK)

Anika Therapeutics Becomes Oversold (ANIK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Anika Therapeutics At $35, Earn 18.8% Annualized Using Options

Commit To Purchase Anika Therapeutics At $35, Earn 18.8% Annualized Using Options

Investors eyeing a purchase of Anika Therapeutics Inc. shares, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Anika Therapeutics Breaks Above 200-Day Moving Average - Bullish For ANIK

Anika Therapeutics Breaks Above 200-Day Moving Average - Bullish For ANIK

In trading on Thursday, shares of Anika Therapeutics Inc. crossed above their 200 day moving average of $38.00, changing hands as high as $39.00 per share.